| Q33773772 | A genome-wide association study on chronic HBV infection and its clinical progression in male Han-Taiwanese |
| Q37408408 | A granulomatous drug eruption induced by entecavir |
| Q39128672 | A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. |
| Q90416293 | Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review |
| Q35185749 | Agents in clinical development for the treatment of chronic hepatitis B. |
| Q45911076 | An alternative and robust synthesis of [(13) C4 ]Baraclude® (entecavir). |
| Q38809405 | Antiviral therapy with nucleotide/nucleoside analogues in chronic hepatitis B: A meta-analysis of prospective randomized trials |
| Q35020817 | Antiviral treatment of patients with HBV-related cirrhosis |
| Q45711101 | BHIVA Guidelines: coinfection with HIV and Chronic hepatitis B virus |
| Q40406133 | BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis B virus infection (2005). |
| Q44555033 | Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus |
| Q34687438 | Chronic hepatitis B: current and future treatment options |
| Q33206221 | Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine |
| Q42879845 | Clinical profile, genotype and management updates of hepatitis B virus |
| Q91230585 | Core inhibitor therapy for chronic hepatitis B |
| Q78073575 | Current literature in. Pharmacoepidemiology and drug safety |
| Q39755479 | Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model |
| Q39652624 | Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro |
| Q46188060 | Entecavir |
| Q35964745 | Entecavir for the treatment of chronic hepatitis B. |
| Q35621693 | Entecavir, FTC, L-FMAU, LdT and others |
| Q34584406 | Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection |
| Q37291331 | Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients |
| Q35094702 | Entecavir: a potent new antiviral drug for hepatitis B. |
| Q36586910 | Entecavir: a review of its use in chronic hepatitis B. |
| Q34563350 | Epidemiology of primary and secondary liver cancers |
| Q36140666 | HIV-1/hepatitis B coinfection |
| Q34154952 | Hepatitis B Therapy in Pregnancy |
| Q45164423 | Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration |
| Q34515671 | How will we use the new antiviral agents for hepatitis B? |
| Q45949258 | Improving outcomes for patients with chronic hepatitis B. |
| Q34841865 | Investigational pharmacologic treatment for liver disease |
| Q41338162 | Lack of an effect of human immunodeficiency virus coinfection on the pharmacokinetics of entecavir in hepatitis B virus-infected patients |
| Q24234212 | Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma |
| Q24236020 | Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma |
| Q24529103 | Management of HBV Infection in Liver Transplantation Patients |
| Q33959006 | Management of viral hepatitis B. |
| Q34200074 | Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay |
| Q42854610 | N-6 Substituted Deoxygenated Derivatives of L-like 5'-Noraristeromycin |
| Q35999165 | Optimal Management of the Hepatitis B Patient Who Desires Pregnancy or Is Pregnant |
| Q44159624 | Oral ganciclovir for treatment of lamivudine-resistant hepatitis B virus infection: a pilot study |
| Q36442537 | Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues |
| Q36957087 | Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis |
| Q38856880 | Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naïve chronic hepatitis B patients |
| Q34727697 | Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue |
| Q33492413 | Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues |
| Q35987869 | Review article: Nucleoside analogues for the treatment of chronic hepatitis B. |
| Q34922618 | Role of antiviral therapy in the prevention of hepatocellular carcinoma |
| Q35026611 | Safety and efficacy of entecavir for the treatment of chronic hepatitis B. |
| Q91230580 | Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial |
| Q42254708 | Similar response to entecavir 0.5 and 1.0 mg in treatment-naïve chronic hepatitis B patients: a case-control study |
| Q40417514 | Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. |
| Q36388323 | The current status of antiviral therapy of chronic hepatitis B. |
| Q42922840 | The efficacy of adefovir dipivoxil, entecavir and telbivudine for chronic hepatitis B treatment: a systematic review |
| Q34592640 | The role of entecavir in the treatment of chronic hepatitis B. |
| Q35920128 | Therapy for HBV Infection in Hemodialysis Patients: Is it Possible? |
| Q38071400 | Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues |
| Q34547915 | Treatment of chronic hepatitis B. |
| Q44407522 | Treatment of hepatitis B |
| Q35207784 | Treatment of hepatitis B in decompensated liver cirrhosis |
| Q40052006 | Understanding the molecular basis of HBV drug resistance by molecular modeling |
| Q44036843 | Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. |
| Q37287635 | Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy |
| Q81321818 | [Treatment of chronic hepatitis B] |
| Q82626752 | [Treatment of chronic hepatitis B] |